natgillin/translations-raw huggingface dataset:
The composition according to any one of the preceding claims, wherein the composition further comprises at least one component selected from the group comprising nucleating agents, stabilizers, impact modifiers, lubricant additives, processing aids and mixtures thereof. 
Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time da sastav nadalje sadrži barem jednu komponentu odabranu iz skupine koja sadrži nukleacijska sredstva, stabilizatore, modifikatore udara, lubrikante aditive, pomoćnike procesiranja 1 njihove smjese.
reacting the compound with in the presence of TMG, NMP and NaI or K2CO3 and MeCNto yield the compound and 
reakciju spoja [image] sa [image] u prisustvu TMG, NMP i NaI ili K2CO3 i MeCN da se proizvede spoj [image] i
A mixing member as claimed in Claim 6, characterized in that the end of the central leg of said flat plate (8) is shaped to engage, in easily releasable manner, a cylindrical pin (10) extending parallel to said axis of rotation (B). 
Članak za miješanje prema patentnom zahtjevu 4, naznačen time, da je kraj centralne nožice navedene ravne ploče (8) oblikovan da zahvati na lako oslobađajući način, cilindrični štift (10) koji se proteže paralelno navedenoj osi rotacije (B).
A compound of formula I: 
Spoj s formulom I:
R1 is selected from the group consisting of phenyl(C1-3)alkyl, pyridinyl(C1-3)alkyl, and furanyl(C1-3)alkyl; wherein phenyl, pyridinyl, and furanyl are optionally substituted with one to three R11 substituents independently selected from the group consisting of C1-3alkoxy; tetrazolyl, C3-6cycloalkylaminocarbonyl; hydroxy(C1-4)alkylaminocarbonyl; C6-10arylaminocarbonyl wherein C6-10aryl is optionally substituted with carboxy or C1-4alkoxycarbonyl; morpholin-4-ylcarbonyl; chloro; fluoro; trifluoromethoxy; and carboxy; 
R! je izabran iz skupine koju čine fenil(C;.g)alkil, piridiniKC,.s)alkil i furani(C,.3)alkil; pri čemu fenil, piridinil i furanil su proizvoljno supstituirani sa jednim do tri R' supstituenta nezavisno izabrana iz skupine koju čine je C1salkoksi; tetrazolil, Cs.gcikloalkilaminokarbonil; hidroksi(C1.4)alkilaminokarbonil; C4_,oarilaminokarbonil pri čemu Cs.qaril je proizvoljno supstituiran sa karboksi ili C,galkoksikarbonil; morfolin-4-ilkarbonil; kloro; fluoro; trifluorometoksi, metoksikarbonil; i karboksi; uz uvjet da ne više od jedan R!! je Csroarilaminokarbonil,;
reducing the EPA derivate of formula (I): wherein -C(=O)X represents a carboxylic acid or a carboxylic ester, to its corresponding alcohol (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-ol (2) by reduction with a reducing agent 
imi X pri čemu -C(=0)X predstavlja karboksilnu kiselinu ili karboksilni ester, u njegov odgovarajući alkohol (52,87,112,147,17Z)-ikoza-5,8,11,14,17-pentaen-1-ol (2) pomoću redukcije sa sredstvom za redukciju
The process of claim 7 wherein L-alaninamide, D-alaninamide or their racemic mixture is employed as an acid addition salt thereof in the presence of a base in an amount sufficient to set free L-alaninamide, D-alaninamide or their racemic mixture from its salt. 
Postupak kao što je u patentnom zahtjevu 12, naznačeno time da se L-alaninamid, D-alaninamid ili njihova Tacemična smjesa primjenjuje kao njihova sol nastala adicijom kiseline u prisutnosti baze u količini koja je dovoljna da se iz njihove soli oslobodi IL-alaninamid, D-alaninamid ili njihova racemična smjesa.
The method of claim 15, wherein the cancer is one or more of cancer of the buccal cavity and/or pharynx, cancer of the digestive tract, cancer of the colon, rectum, or anus, cancer of the respiratory tract, breast cancer, cancer of the cervix uteri, vagina, or vulva, cancer of the uterine corpus or ovary, cancer of the male genital tract, cancer of the urinary tract, bone or soft tissue cancer, Kaposi sarcoma, melanoma of the skin, ocular melanoma, non-melanoma eye cancer, cancer of the brain and central nervous system, cancer of the thyroid and other endocrine glands, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, myeloma, renal cancer, colorectal cancer, lung cancer, breast cancer, pancreatic cancer, prostate cancer, gastric cancer, GIST or glioblastoma. 
Farmaceutski sastav za uporabu prema zahtjevu 12, pri čemu je karcinom karcinom usne šupljine 1 ždrijela, karcinom probavnog trakta, karcinom debelog crijeva, rektuma i anusa, karcinom respiratornog trakta, karcinom dojke, karcinom grlića maternice, vagine i vulve, karcinom tijela maternice 1 jajnika, karcinom muškog genitalnog trakta, karcinom urinarnog trakta, karcinom kostiju i mekog tkiva, Kaposijev sarkom, melanom kože, melanom oka, nemelanomski karcinom oka, karcinom mozga i središnjeg živčanog sustava, karcinom žlijezde štitnjače i drugih endokrinih žlijezda, Hodgkinov limfom, ne-Hodgkinov limfom, ili mijelom kao što su karcinom bubrega, kolorektalni karcinom, karcinom pluća, karcinom dojke, karcinom gušterače, karcinom prostate, karcinom želuca, gastrointestinalni stromalni tumor (GIST) ili glioblastom.
The crystalline 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione of claim 5, which has a differential scanning calorimetry thermogram comprising an endotherm with a maximum at about 269 °C; or which is unsolvated. 
Kristalni 3-(4-amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-dion u skladu s patentnim zahtjevom 2, naznačen time što pikovi difrakcije rendgenskih zraka na prahu su na 15,8, 22,2 i 26.7 stupnjeva 2θ.
NB: The final volume in the well is 250 µl; the final dilution of r-hlL-18BP 1:5. 
Opaska: Konačan volumen u jažici je 250 ul; konačno razrjeđenje r-hIL-18Bp je 1:5.
Reactions are stopped by the addition of an equal volume of acetonitrile. 
Reakcije su zaustavljene dodavanjem jednakog volumena acetonitrila.
The pharmaceutical dosage form according to any of the preceding claims, wherein the pharmacologically active agent according to general formula (I) has a stereochemistry according to general formula (I') wherein R is defined as in claim 1. 
Farmaceutski oblik doziranja za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time što farmakološki aktivno sredstvo prema općoj formuli (I) ima stereokemiju prema općoj formuli (T) pri čemu je R definiran kao u patentnom zahtjevu 1.
Compounds of formula (11) may be prepared from a compound of formula (111) wherein R6 is 2-hydroxyphenyl by reaction with carbonyldiimidazole or thiocarbonyldiimidazole in a suitable solvent such as dichloromethane and subsequent reaction of the product thus formed with aqueous acetone. 
Spojeve formule (11) može se dobiti iz spoja formule (111), gdje Ry je 2-hidroksifenil, reakcijom s karbonildiimidazolom ili tiokarbonildiimidazolom, u pogodnom otapalu, poput diklormetana, te naknadnom reakcijom tako dobivenog produkta s vodenom otopinom acetona,
A wall structure comprising 
Zidna struktura sadrži
substituting X with PLG by reaction of a reagent PLG-H in the presence of a base, to obtain a compound of formula VII. 
(ii) supstitucija X s PLG pomoću reakcije reagensa PLG-H u prisutnosti baze, kako bi se dobio spoj formule VII.
The crystalline form III obtained from acetone/n-hexane has a DRX as shown in Fig. 10 and/or a DSC as shown in Fig. 11 and/or an IR as shown in Fig. 12 . 
Korteksolon-17a-propionat u kristalnom obliku III u skladu s patentnim zahtjevom 15, naznačen time što ima DR.X spektar, kao što je prikazan na Slici 10 1 DSC spektar, kao što je prikazan na Slici 11, te što ima IR spektar, kao što je prikazan na Slici 12.
use of the compound of the aforementioned (1) for manufacture of an insulin sensitizer; 
Uporaba, naznačena time, da se koristi spoj prikazan formulom (I)
In one embodiment, the modified sulfamidase has a relative content of natural glycan moieties of around 25% of the content of natural glycan moieties in unmodified recombinant sulfamidase. 
Modificirana sulfamidaza sukladno patentnom zahtjevu 1, ima relativan sadržaj preostalih nedirnutih dijelova prirodnog glikana od oko 25 % od sadržaja dijelova prirodnog glikana u nemodificiranoj rekombinanntnoj sulfamidazi.
A nucleic acid sequence or nucleic acid sequences which result in the expression of an anti-human IL-6 antibody or antibody fragment according to claim 1. 
Slijed nukleinskih kiselina koji kodira anti-IL-6 protutijelo sukladno bilo kojem od patentnih zahtjeva 1-3. Vektor koji sadrži slijed nukleinske kiseline sukladno patentnom zahtjevu 4.
Subsequently add the beaten eggs and the sieved flour. 
Potom dodati istučena jaja 1 prosijano brašno.
A compound for use according to claim 12, wherein the disorder is a cognition disorder. 
Spoj prema patentnom zahtjevu 1 za uporabu u liječenju poremećaja u skladu s patentnim zahtjevom 23, naznačen time, da poremećaj jest kognitivni poremećaj.
The device 1 comprises a third suction cup 5 active on a second external lateral face of a flexible container, preferably in correspondence with the inlet thereof. 
Uređaj 1 ima treću usisnu čašicu 5 koja djeluje na drugu vanjsku bočnu plohu savitljivog spremnika, za koju plohu je poželjno da je u vezi s ulaznim otvorom spremnika.
The process of any of the previous claims, wherein the calcium carbonate is a ground calcium carbonate, modified calcium carbonate, or precipitated calcium carbonate, or mixtures thereof. 
Postupak prema bilo kojem od prethodnih zahtjeva, pri čemu je kalcij karbonat mljeveni kalcij karbonat, modificirani kalcij karbonat, gdje je modificirani kalcij karbonat mljeveni ili istaloženi kalcij karbonat sa modifikacijom površine i/ili interne strukture, ili istaloženi kalcij karbonat, ili njihove smjese.
The antibody of claim 35, wherein the label is ruthenium, 111In-DOTA, 111Indiethylenetriaminepentaacetic acid (DTPA), horseradish peroxidase, alkaline phosphatase and beta-galactosidase, or poly-histidine. 
Protutijelo u skladu s patentnim zahtjevom 35, naznačeno time što je biljeg rutenij, 111In-DOTA, 111In-dietilentriaminpentaoctena kiselina (DTPA), peroksidaza iz hrena, alkalna fosfataza i B-galaktozidaza, ili polihistidin.
Chiro CLEC CR enzyme is added with moderate agitation followed by addition of compound (d) (10.0 g, 47.6 mmol) in toluene (100 mL). 
Chiro CLEC CR enzim dodaje se uz umjereno miješanje, te se doda spoj (d) (10,0 g, 47,6 mmol) u toluenu (100 ml).
In a particular embodiment of the invention that relates to the treatment of cancers, the cancer is identified as p53wildtype (p53WT). In another particular embodiment, the cancer is identified as p53WT and CDKN2A mutant. 
Spoj za uporabu u postupku liječenja raka kod subjekta kojemu je ono potrebno prema bilo kojem od zahtjeva 5-12, pri čemu je rak identificiran kao divlji tip p53 (p53WT).
an elongated outer body bearing a dispensing nozzle for dispensing the substance in the form of an aerosol, the elongated outer body extending in a longitudinal direction and having a centrally extending longitudinal axis; 
izduženo vanjsko tijelo (2) koje nosi mlaznicu (53) za ispuštanje tvari u obliku aerosola; unutarnje tijelo (3), koje je se nalazi unutar navedenog vanjskog tijela (2); i
Pet-ether (30-40 °C) (56 ml) was added to the mixture with stirring and the crude B-DHTBZ was collected as a white solid by filtration. 
U smjesu se doda petrolej eter (30-40 "C) (56 ml) uz miješanje i filtriranjem se sakupi sirovi B-DHTBZ kao bijela p
B represents a -heterocyclyl group wherein said heterocyclyl group may be optionally substituted by 1, 2 or 3 Ra groups; 
B predstavlja –heterociklil grupu gdje navedena heterociklil grupa može biti opcionalno supstituiran s 1, 2 ili 3 Ra grupe;
The effect of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride on the [35S]GTPYS specific binding to membranes preparation from CHO cells expressing the human H3R at different levels was also studied. 
Također je proučavan i učinak 1-[3-[3-(4-klorfenil)propoksilpropil|-piperidin monoklorida na specifično vezivanje ['*S]GTPyS na preparate membrana iz CHO stanica koje eksprimiraju humani H3R na različitim razinama.
The spatial logical game according to claim 10, wherein the outer surface of the terminal portions adapted for allowing the grabbing and displacing the internal and middle body portions is shaped to correspond to the outer shape of the external body portion. 
Igra prostorne logike u skladu s patentnim zahtjevom 10, karakterizirana time što je vanjska površina krajnjih dijelova (206, 208) prilagođena za omogućavanje hvatanja i odmicanja unutarnjeg i srednjeg dijela tijela (202, 203) oblikovana da odgovara vanjskom obliku izvanjskog dijela tijela (204),
A developer supply container according to any one of Claims 1 - 18, further comprising a nozzle portion connected to said pump portion and having an opening at a free end thereof, the opening of said nozzle portion being adjacent to said discharge opening. 
Spremnik za nadopunjavanje razvijača u skladu s bilo kojim od patentnih zahtjeva 1-18, naznačen time što dodatno sadrži mlaznicu (52), povezanu s navedenim crpnim dijelom (2a), te koja ima otvor na svojem slobodnom kraju, gdje je otvor navedene mlaznice (47) uz navedeni otvor za ispuštanje (3a).
A propulsion unit nozzle (1) according to claim 1 or 2, wherein the hydrodynamic elements are of a casted non-metallic material. 
Pogonska jedinica mlaznice (1) prema zahtjevu 1 ili 2, naznačena time, da su hidrodinamički elementi (12) od lijevanog nemetalnog materijala.
The pharmaceutical dosage form according to claim 8 wherein said mannitol is present from 3 to 40% by weight based on the total weight of said pharmaceutical dosage form. The pharmaceutical dosage form according to claim 1 comprising: 
Farmaceutski dozni oblik prema zahtjevu 9, naznačen time, da je navedeni manitol prisutan s 3 do 40 masenih %, poželjno s 5 do 40 masenih % na osnovi ukupne mase navedenog farmaceutskog doznog oblika.
A binding molecule capable of binding L1 of any of claims 1 to 3, for use in a method of sensitizing tumor cells in a patient for the treatment with a chemotherapeutic drug or with radiotherapy. 
Vežuća molekula koja se može vezati na LI u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što je namijenjena upotrebi u postupku sensibiliziranja tumorskih stanica kod pacijenta radi liječenja kemoterapijskom lijekom ili radioterapijom.
Then, the reaction mixture was concentrated under vacuum and the residue was purified by preparative HPLC using MeOH/water containing 0.1% TFA (gradient elution). 
Zatim, reakcijska smjesa je koncentrirana pod vakuumom i ostatak je pročišćen pomoću preparativne HPLC primjenom MeOH/vode koji sadrži 0.1% TFA (eluiranje pomoću gradijenta).
the stream of products derived from the oxychlorination reactor, from which the 1,2-dichloroethane has been extracted, is recycled to step a). 
struja produkata dobivenih iz reaktora za oksidaciju za kloriranje, iz koje je ekstrahiran 1,2-dikloroetan, se reciklira u korak a).
Process according to any of claims 1 to 3, characterized in that the oxidant of step b) is selected from the group consisting of hydrogen peroxide, sodium percarbonate, potassium percarbonate, sodium perborate, potassium perborate, sodium permanganate, potassium permanganate, sodium dichromate, potassium dichromate, and hydrates thereof. 
Proces prema zahtjevu 5, naznačen time što je oksidans odabran iz skupine koja se sastoji od vodikovog peroksida, natrijevog perkarbonata, kalijevog perkarbonata, natrijevog perborata, kalijevog perborata, natrijevog permanganata, kalijevog permanganata, natrijevog dikromata, kalijevog dikromata i njihovih hidrata.
The pharmaceutical composition of Claim 21, wherein the additional therapeutic agent is selected from the group consisting of steroids, non-steroidal antiinflammatory agents, antihistamines, analgesics, and suitable mixtures thereof. 
Farmaceutski pripravak prema zahtjevu 60, naznačen time da je dodatno terapeutsko sredstvo je odabrano iz HR P20110180 T1 skupine koja sadrži steroide, ne-steroidna protuupalna sredstva, antihistaminike, analgetike, i njihove pogodne mješavine.
The method of claim 15, whereby the reference setup stage includes an electrical interfacing stage including a combination of manually entering information into the device and providing data sourced from at least one said current transformer electrical connector connected to the electrical energy diagnostic device. 
Metoda prema zahtjevu 11 ili 12, pri čemu se unos referentnih podataka odnosi na fazu povezivanja koja pak uključuje kombinaciju ručnog unosa podataka u uređaj (10) 1 dobivanje podataka s najmanje jednog električnog konektora za strujne transformatore spojenog na navedeni uređaj (10).
substituted and unsubstituted C1-3 alkyl. 
(6) supstituirani i nesupstituirani C,.salkil,
The salt of claim 8, characterized by spectral d-spacing absorption bands obtained from an X-ray powder diffraction pattern of the same or essentially the same as 3.57,4.80 and 4.99 angstroms. 
Sol prema zahtjevu 8, naznačena time što su d-razmaci spektralnih apsorpcijskih vrpci, koje su dobivene rendgenskom difrakcijom praška, jednaki ili u biti jednaki 3.57,4.80 1 4.99 angstrema.
is H; C1-C4 alkyl optionally substituted by one or more halogen atoms; C1-C4 alkoxy optionally substituted by one or more halogen atoms; halogen; C6-C14 aryl; —(C0-C4 alkyl)-3 to 14 membered heterocyclic group, wherein the heterocyclic group contains at least one heteroatom selected from N, O and S; or —NR11R12, wherein the aryl and heterocyclic groups are each optionally substituted by one or more Z substituents. 
R' je C,-Cg alkil opcijski supstituiran s jednim ili više atoma halogena; C,-Cz alkoksi opcijski supstituiran s jednim ili više atoma halogena; halogen; NR''R'", Cg-Cua aril; ili (Co-Cu alkil)- 5- do 6-člana heterociklička skupina, gdje heterociklička skupina sadrži najmanje jedan heteroatom odabran od N, O 15, pri čemu je svaka od arilne i heterocikličke skupine opcijski supstituirana s jednim ili više Z supstituenata.
A combination for use according to claim 1 wherein the EGFR inhibitor is erlotinib or a monoclonal antibody. 
EGFR inhibitor, pri čemu EGFR inhibitor je cetuksimab ili erlotinib, te po izboru,
A process for preparing a compound as claimed in claim 1, characterized by reacting an intermediate of formula (IV) with an intermediate of formula (V) wherein W is an appropriate leaving group with the variables as defined in claim 1; 
Postupak za dobivanje spoja prema zahtjevu 1, naznačen time da sadrži a) reakciju intermedijera prema formuli (IV) sa intermedijerom prema formuli (V) pri čemu W je prikladna odlazna skupina 6
The system of claim 1, wherein at least part of the introducer (102) and at least part of the ablation probe (120) have complementary shapes preventing rotation of the ablation probe with respect to the introducer. 
Sustav prema zahtjevu 1, naznačen time da barem dio uvodnika (102) i barem dio sonde za ablaciju (120) imaju komplementarne oblike koji sprječavaju rotaciju sonde za ablaciju u odnosu na uvodnik.
Step 10—PEGylation of the Terminal —NH2 Group: 
Datum objave europske prijave patenata:
Complex of claim 6 or pharmaceutical composition of claim 7 for use as a medicament. 
Kompleksni spoj u skladu s patentnim zahtjevom 5 ili farmaceutski spoj u skladu s patentnim zahtjevom 6 za uporabu kao lijek.
Energy and weight efficient building block, manufacturing and application process thereof 
ENERGETSKI I TEŽINSKI UČINKOVIT GRAĐEVINSKI BLOK, NJEGOVA PROIZVODNJA I POSTUPAK PRIMJENE
An isolated nucleic acid composition according to claim 4 wherein said first nucleic acid encodes SEQ ID NO:21 and said second nucleic acid encodes SEQ ID NO:22. 
Izolirano protutijelo prema zahtjevu 1 naznačeno time da teški lanac sadrži SEQ ID NO:21 i lagani lanac sadrži SEQ ID NO:22.
The coating of claim 10, wherein the coating is capable of being modified to a conductive coating with sacrificial corrosion protection. 
Sastav obloge iz patentnog zahtjeva 7, pri čemu se obloga može preoblikovati u provodljivu oblogu s potrošnom zaštitom od korozije.
The following Preparations illustrate the preparation of certain starting materials. 
Slijedeći preparati ilustriraju dobivanje izvjesnih polaznih materijala.
The method of section M, wherein the Layer 1 signaling data has Program Specific Information(PSI) and Service Information(SI) reprocessing information for each Physical Layer Pipe (PLP), and the PSI/SI reprocessing information indicates whether or not a PSI/SI reprocessing has been performed. 
Metoda iz patentnog zahtjeva 13, gdje signalni podaci Razine 1 imaju programski specifičnu informaciju (PSI) i servisnu informaciju (SI) ponovo obrađuju informaciju za svaku cijev fizičke razine (PLP), i ponovna obrada PSI/SI informacija ukazuje je li ili nije provedena ponovna obrada PSISI.
evaporation of solvent was carried out using a rotary evaporator under reduced pressure (4.5-30 mmHg) with a bath temperature of up to 50°C; 
(ii) evaporacija otapala je provedena uporabom rotacijskog evaporatora uz smanjen tlak (4.5-30 mmHg) uz temperaturu kupke do 50" C;
An oligonucleotide decoy, comprising a sequence having at least 85% identity with SEQ ID NO:33. 
Oligonukleotidna zamka, naznačena time, da se sastoji od sekvence od SEQ ID NO:41.
A method for treating a bone-related disorder in a mammalian subject which comprises providing to a subject in need of such treatment a pharmaceutical composition according to any one of claims 28, 29 or 30. The method according to claim 37, wherein the bone-related disorder is at least one of primary and secondary osteoporosis, osteopenia, osteomalacia, osteogenesis imperfecta (OI), avascular necrosis (osteonecrosis), fractures and implant healing (dental implants and hip implants), bone loss due to other disorders such as bone loss associated with HIV infection, cancers, or arthritis. 
Protutijelo prema bilo kojem od zahtjeva 1 do 4, ili farmaceutski sastav prema bilo kojem od zahtjeva 8 do 11, naznačen(o) time, da se upotrebljava za liječenje ili profilaksu patološkog poremećaja koji je posredovan sklerostinom ili je povezan s povećanjem razine sklerostina, pri čemu je patološki poremećaj barem jedan od sljedećih: primarna i sekundarna osteoporoza, osteopenija, osteomalacija, osteogenesis imperfecta, vaskularna nekroza također poznata pod nazivom osteonekroza, frakture i zacjeljivanje implantatima uključujući dentalne implantate i implantate za kuk, gubitak kostiju zbog ostalih poremećaja kao što je gubitak kostiju povezan s HIV-infekcijom, rakom ili artritisom.
p and s independently represent an integer from 0 to 3, wherein the sum of p and s minimally should be 2, and when p = 0 or s = 0 then the carbon atom marked with * is directly bound to W; 
P i s neovisno predstavljaju cijeli broj od O do 3, pri čemu zbroj p 1 s treba minimalno biti 2,ikadap=0ilis=0 tada je ugljikov atom označen sa * izravno vezan za W;
0.052 Additional Excipients 
0.052 Dodatne pomoćne tvari
reacting the above compound of formula IIa with 2-bromo-4-fluorophenol or 2-bromo-4-fluorophenyl acetate by means of a palladium catalysed C-C coupling reaction, to obtain a compound of formula XIa in the form of diastereoisomeric mixture (S,R+R,R) 
HO \, U _b) reakciju gore navedenog spoja formule Ila sa 2-bromo-4-fluorofenolom, da bi se dobio spoj formule Illa u obliku dijastereoizomerne smjese (S, R+R, R)
A composition as claimed in claim 1, wherein a salt of alginic acid is sodium, potassium or calcium alginate. 
Smjesa prema zahtjevu 1, gdje je sol alginske kiseline natrijev, kalijev 1li kalcijev alginat.
which further comprises at least one stabilizer, which is lyophilized, or which comprises one or more anti-IL-6 antibodies comprising (a) a VH chain having the amino acid sequence of SEQ ID NO: 3, 18, or 19; and (b) a VL chain having the amino acid sequence of SEQ ID NO: 2 or 20, or a chimeric antibody, a humanized antibody or a fragment derived therefrom. 
Farmaceutski ili dijagnostički sastav iz patentnog zahtjeva 7, a) koji nadalje sadrži najmanje jedan stabilizator, b) koji je liofiliziran, ili c) koji sadrži jedno ili više anti-IL-6 protutijela koja sadrže (a) Vg lanac koji ima aminokiselinski slijed SEQ ID NO:3, 18 ili 19; 1 (b) VL lanac koji ima aminokiselinski slijed SEQ ID NO:2 1li 20.
The fumarate salt of claim 3, wherein at least 99% by weight of the fumarate salt is in a single crystalline form. 
Maleat sol sukladno patentnom zahtjevu 12 ili 13, pri čemu je najmanje 99% težine soli u jednom kristalnom obliku.